Table 2 Patient characteristics according to mutation status.
BRAF-V600Emt | RASmt | RAS&BRAFwt | Totala | p-value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
123 | 17% | 365 | 52% | 220 | 31% | 765 | 100% | |||
Median age (range) | 73 (36–96) | 72 (30–99) | 70 (28–95) | 72 (28–99) | 0.078 | |||||
Total | 123 | 100% | 365 | 100% | 220 | 100% | 765 | 100% | ||
Age groups | ≤70 years | 45 | 37% | 150 | 41% | 107 | 49% | 313 | 41% | 0.066 |
>70 years | 78 | 63% | 215 | 59% | 113 | 51% | 452 | 59% | ||
Sex | Male | 49 | 40% | 198 | 54% | 128 | 58% | 405 | 53% | 0.004 |
Female | 74 | 60% | 167 | 46% | 92 | 42% | 360 | 47% | ||
Primary tumour | Right colon | 89 | 73% | 117 | 32% | 57 | 26% | 291 | 38% | <0.001 |
location | Left colon | 21 | 17% | 88 | 24% | 86 | 39% | 207 | 27% | |
Rectum | 12 | 10% | 158 | 44% | 77 | 35% | 262 | 34% | ||
Unknown/multiple | 1 | – | 2 | – | – | – | 5 | – | – | |
Primary resection | No | 57 | 46% | 154 | 42% | 81 | 37% | 339 | 44% | 0.199 |
Yes | 66 | 54% | 211 | 58% | 139 | 63% | 426 | 56% | ||
Tumour grade | Low | 45 | 38% | 253 | 79% | 147 | 72% | 467 | 68% | <0.001 |
High | 73 | 62% | 68 | 21% | 57 | 28% | 216 | 32% | ||
Missing | 5 | – | 44 | – | 16 | – | 82 | – | – | |
Presentation of metastases | Synchronous | 81 | 66% | 227 | 62% | 152 | 69% | 510 | 67% | 0.232 |
Metachronous | 42 | 34% | 138 | 38% | 68 | 31% | 255 | 33% | ||
Number of metastatic sites | 1 | 53 | 43% | 173 | 47% | 112 | 51% | 367 | 48% | 0.223 |
2 | 53 | 43% | 123 | 34% | 76 | 35% | 273 | 36% | ||
3–5 | 17 | 14% | 69 | 19% | 32 | 15% | 125 | 16% | ||
Metastatic sites | Liver | 63 | 51% | 246 | 67% | 147 | 67% | 498 | 65% | 0.003 |
Lung | 39 | 32% | 183 | 50% | 65 | 30% | 305 | 40% | <0.001 | |
Peritoneum | 49 | 40% | 79 | 22% | 68 | 31% | 206 | 27% | <0.001 | |
Lymph nodes | 41 | 33% | 86 | 24% | 50 | 23% | 196 | 26% | 0.062 | |
Bone | 6 | 5% | 16 | 4% | 7 | 3% | 30 | 4% | 0.692 | |
Brain | 5 | 4% | 8 | 2% | 1 | 1% | 16 | 2% | 0.056 | |
Other | 15 | 12% | 36 | 10% | 27 | 12% | 80 | 10% | 0.599 | |
ECOG PS | 0 | 25 | 20% | 144 | 40% | 81 | 37% | 252 | 33% | <0.001 |
1 | 36 | 29% | 112 | 31% | 74 | 34% | 243 | 32% | ||
2–4 | 62 | 50% | 109 | 30% | 65 | 30% | 269 | 35% | ||
Not available | – | – | – | – | – | – | 1 | – | – | |
MMR-status | pMMR | 56 | 67% | 235 | 96% | 139 | 91% | 438 | 90% | <0.001 |
dMMR | 28 | 33% | 9 | 4% | 13 | 9% | 50 | 10% | ||
Not tested | 39 | – | 121 | – | 66 | – | 277 | – | – | |
Type of treatment | Metastasectomy | 18 | 15% | 113 | 31% | 79 | 36% | 213 | 28% | <0.001 |
Systemic therapy only | 62 | 50% | 169 | 46% | 93 | 42% | 334 | 44% | ||
Best supportive care | 43 | 35% | 83 | 23% | 48 | 22% | 217 | 28% | ||
Not known | – | – | – | – | – | – | 1 | – | – | |
